Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.

Lai X, Chen M, Huang Y, Cheng Y

Open source

DOI
10.1093/jvimsj/aalag193
Published
2026 Sep 1
Container
Journal of veterinary internal medicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1093/jvimsj/aalag193,
  title = {Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.},
  author = {Lai X and Chen M and Huang Y and Cheng Y},
  year = {2026},
  journal = {Journal of veterinary internal medicine},
  doi = {10.1093/jvimsj/aalag193},
  url = {https://doi.org/10.1093/jvimsj/aalag193}
}

RIS

TY  - JOUR
TI  - Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.
AU  - Lai X
AU  - Chen M
AU  - Huang Y
AU  - Cheng Y
PY  - 2026
JO  - Journal of veterinary internal medicine
DO  - 10.1093/jvimsj/aalag193
UR  - https://doi.org/10.1093/jvimsj/aalag193
ER  - 

APA

X, L., M, C., Y, H., & Y, C. (2026). Post-marketing safety monitoring of sodium-glucose cotransporter 2 inhibitors for diabetes in cats: a pharmacovigilance study based on the FDA ADAE database.. Journal of veterinary internal medicine. https://doi.org/10.1093/jvimsj/aalag193

Source records